Aprea Therapeutics Inc Cash Flow-to-Debt Ratio
Aprea Therapeutics Inc cash flow-to-debt ratio. Aprea Therapeutics Inc (APRE) has a Cash Flow-to-Debt Ratio of -0.86x as of June 2026, meaning its operating cash flow of $-3.28 Million could theoretically repay -1% of its total liabilities ($3.82 Million) in one year. See Aprea Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aprea Therapeutics Inc (2007–2025)
Cash flow-to-debt ratio of Aprea Therapeutics Inc from 2007 to 2025. Historical debt coverage capacity for Aprea Therapeutics Inc across 10 annual periods. Also explore Aprea Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Aprea Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2007–2025)
Aprea Therapeutics Inc cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Aprea Therapeutics Inc. For the full cash flow conversion analysis, see APRE operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.69x | $-12.89 Million | $3.49 Million | ▼ -27.3% |
| 2024 | -2.90x | $-13.56 Million | $4.67 Million | ▼ -4.5% |
| 2023 | -2.78x | $-12.18 Million | $4.39 Million | ▲ +49.9% |
| 2022 | -5.54x | $-25.01 Million | $4.51 Million | ▼ -7.6% |
| 2021 | -5.15x | $-37.69 Million | $7.32 Million | ▼ -89.9% |
| 2020 | -2.71x | $-41.80 Million | $15.41 Million | ▲ +4.9% |
| 2019 | -2.85x | $-26.71 Million | $9.36 Million | ▼ -2096.8% |
| 2018 | -0.13x | $-15.25 Million | $117.46 Million | ▲ +43.9% |
| 2017 | -0.23x | $-14.00 Million | $60.53 Million | ▲ +70.4% |
| 2007 | -0.78x | $-1.90 Million | $2.43 Million | — |